Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

FDA Approves VYVANSE CII Label Change To Include Supplementary Clinical Data Supporting Efficacy At 13 Hours Postdose In Children Age 6-12 With ADHD
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved a change to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment VYVANSE® (lisdexamfetamine dimesylate) CII, to include supplemental data that demonstrated significant ADHD symptom control in children aged 6 to 12 from the first time point measured (1.5 hours) through 13 hours postdose. VYVANSE is now the first and only oral ADHD stimulant treatment to have 13-hour postdose efficacy data for pediatric patients included in its product labeling.

Experts: Big Tobacco Dead By 2047, Possibly Sooner
President Barack Obama"s signature on a bill this week to grant the Food and Drug Administration (FDA) regulatory authority over tobacco was historic, and represents a step in the march to eliminate tobacco use in this country by 2047, two national tobacco experts said recently (June 25).
News of the day
A New Plug For The Hole In The Heart: New Procedure May Help Save Lives Of Those Affected By Common Congenital Heart Defect
Heart specialists at St. Joseph Hospital in Orange, Calif. have performed a new procedure in which they repaired a hole in the patient"s heart through a tiny incision, offering the patient a much safer alternative verses open heart surgery.
Endocrinology

Medtronic Annual Meeting Date Scheduled For August 27, 2009

The board of directors of Medtronic, Inc. (NYSE: MDT), announced that the company"s annual meeting of shareholders will be held at 10:30 a.m., Central Daylight Time, on Thursday, August 27, 2009 at Medtronic World Headquarters, located at 710 Medtronic Parkway, Minneapolis, Minnesota. Shareholders of record at the close of business on June 29, 2009, will be eligible to vote at the meeting. About Medtronic Medtronic, Inc. , headquartered in Minneapolis, is the world"s leading medical technology company, alleviating pain, restoring health, and extending life for people with chronic disease. Medtronic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009